| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/04/2009 | US7569567 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide derivatives, their preparation and therapeutic use |
| 08/04/2009 | US7569566 Inhibitors of tyrosine kinases |
| 08/04/2009 | US7569565 Etifoxine derivatives; corticoids; methyl-d-aspartic acid antagonists |
| 08/04/2009 | US7569564 Such as 4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1 ,3]oxazin-6-yl)-thiophene-2-carbonitrile; estrogen receptor agonists, progesterone receptor antagonists; hormone replacement therapy |
| 08/04/2009 | US7569563 antiviral agents, in particular against cytomegaloviruses; Ethyl{(2RS,6SR)-4-[3-{[(2,4-dichlorobenzyl)amino]carbonyl}-6-fluoro-8-methoxy-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydroquinolin-7-yl]-2,6-dimethylpiperazin-1-yl}ethanoate hydroformate |
| 08/04/2009 | US7569562 1-Methyl-1H-imidazole-4-sulfonic acid (4-bromo-benzyl)-(2-oxo-azepan-3-yl)-amide; for treating or preventing cognitive disorders, such as Alzheimer's Disease |
| 08/04/2009 | US7569561 For treating carcinoma chosen from cervical, breast, colon, head and neck, lung, pancreas, prostate, sarcomas, leukaemias, lymphomas, melanomas and gliomas |
| 08/04/2009 | US7569560 Three phases of adminisering a progestogen such as norethindrone acetate and an estrogen such as ethinyl estradiol, followed by placebo wherein the amount of estrogen in the Phase 2 composition is at least 5 mcg greater than that of phase 1 and 3; enables the user to maintain menstrual cycle control |
| 08/04/2009 | US7569559 Carbon-based diazeniumdiolated molecules release NO spontaneously under physiological conditions without nitrosamine formation; bacteriostats, bacteriocides; blood platelet storage |
| 08/04/2009 | US7569558 Chromium benfotiamine picolinate, copper adenosine triphosphate gluconate or vanadium pyridoxal-5-phosphate oxoglycinate; modulation of metalloenzymes; antiinflammatory, skin whitening, wrinkle reduction, skin aging control, cellular antioxidant, acne control, hair growth modulation |
| 08/04/2009 | US7569557 Compositions of estrogen-cyclodextrin complexes |
| 08/04/2009 | US7569556 Fluoroquinolone antibiotic such as ofloxacin, and chemically modified polysaccharide such as oxidized starch reaction product; time release adjuvant solution |
| 08/04/2009 | US7569555 By administering a cyclic di-GMP or a cyclic dinucleotide analogue; use as vaccine adjuvant |
| 08/04/2009 | US7569554 Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents |
| 08/04/2009 | US7569553 Dna bacteria; activate lymphocytes; nucleotide sequences; antigens; administering cytokines |
| 08/04/2009 | US7569551 Administering composition effective to inhibit expression of testosterone-repressed prostate message-2 gene in renal cell cancer |
| 08/04/2009 | US7569550 New antibiotics that are erythromycin A and azithromycin derivatives; broad spectrum, use against antibiotic resistant strains such as erythromycin resistant strains of Streptococcus pneumoniae, S. pyogenes and S. aureus |
| 08/04/2009 | US7569549 Crystallizing in water-miscible solvent, water, and mineral/organic acid |
| 08/04/2009 | US7569536 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene |
| 08/04/2009 | US7569387 Specifically binds an MK61 polypeptide produced by immunizing an animal |
| 08/04/2009 | US7569232 Medium chain peroxycarboxylic acid compositions |
| 08/04/2009 | US7569230 Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
| 08/04/2009 | US7569216 Anti-virus therapy for respiratory diseases |
| 08/04/2009 | US7569214 Hydrolysing water-soluble polyoxyethylene glycol segment having alkoxide ion or thiolate ion with ortho ester comprised of suitable leaving group (methanesulfonate) |
| 08/04/2009 | US7569213 Immunotherapeutic agent |
| 08/04/2009 | US7569212 Impregnation of contact lenses in a solution which comprises one or more suitable components for the treatment, care and/or protection of the eye |
| 08/04/2009 | US7569210 natural soap bar for cleaning the skin, comprising titanium dioxide and zinc oxide sunscreen agents; providing protection against sunlight; also contains balm of Gilead, chlorophyll, olive oil, aloe vera, and lemon juice; protection of skin |
| 08/04/2009 | CA2653189A1 Estrogenic compounds, process for their production and pharmaceutical uses thereof |
| 08/04/2009 | CA2566440C An antimycobacterial pharmaceutical composition |
| 08/04/2009 | CA2560252C Process for the production of atorvastatin calcium in amorphous form |
| 08/04/2009 | CA2536251C Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| 08/04/2009 | CA2523987C Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery |
| 08/04/2009 | CA2506081C Water-soluble mesoporphyrin compounds and methods of preparation |
| 08/04/2009 | CA2496476C Therapeutic use |
| 08/04/2009 | CA2462606C Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
| 08/04/2009 | CA2457996C Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same |
| 08/04/2009 | CA2436511C Use of flumazenil to produce a medicament for the treatment of cocaine dependency |
| 08/04/2009 | CA2434228C Biphenyl derivatives |
| 08/04/2009 | CA2433785C Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 08/04/2009 | CA2420348C Non-hormonal vaginal contraceptive |
| 08/04/2009 | CA2417837C Compositions for ameliorating attention-deficient/hyperactivity disorder |
| 08/04/2009 | CA2411047C Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| 08/04/2009 | CA2406057C Methods and compositions for modulating alpha adrenergic receptor activity |
| 08/04/2009 | CA2392367C Composition and method for treatment of otitis media |
| 08/04/2009 | CA2357014C Method of using (2-imidazolin-2-ylamino) quinoxalines in treating neural injury |
| 08/04/2009 | CA2356212C Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt |
| 08/04/2009 | CA2347447C Buffered compositions for dialysis |
| 08/04/2009 | CA2334727C Tetrahydroquinoline derivatives as glycine antagonists |
| 08/04/2009 | CA2322745C Method of treating neuroma pain |
| 08/04/2009 | CA2275425C Aminoindan derivatives |
| 08/04/2009 | CA2247009C Cryptic peptides and method for their identification |
| 08/04/2009 | CA2243649C Bioresponsive pharmacologically-active polymers and articles made therefrom |
| 08/04/2009 | CA2221110C Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension |
| 08/04/2009 | CA2207850C Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor |
| 08/04/2009 | CA2205184C The treatment of autoimmune disease using 2-amino purine derivatives |
| 08/04/2009 | CA2201115C Hydration compositions for human or animal bodies |
| 07/30/2009 | WO2009094668A1 New 2,3,4,5-tetrahydro-1h-pyrido[ 4,3-b] indole compounds and methods of use thereof |
| 07/30/2009 | WO2009094641A2 Topically active steroids for use in interstitial pulmonary fibrosis |
| 07/30/2009 | WO2009094580A2 Nano-devices having releasable seals for controlled release of molecules |
| 07/30/2009 | WO2009094577A2 Mesophasic forms of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use |
| 07/30/2009 | WO2009094563A2 Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use |
| 07/30/2009 | WO2009094560A2 Thienopyranones as kinase inhibitors |
| 07/30/2009 | WO2009094528A1 TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS |
| 07/30/2009 | WO2009094473A1 Methods and compositions for topical treatment of medical conditions including wounds and inflammation |
| 07/30/2009 | WO2009094462A1 A crystalline synthetic intermediate for pyrrolidin-3-yl-glycylaminoalkylboronates |
| 07/30/2009 | WO2009094460A2 Volatile anesthetic compositions and methods of use |
| 07/30/2009 | WO2009094459A1 Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
| 07/30/2009 | WO2009094456A2 Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection |
| 07/30/2009 | WO2009094438A1 Heteroaryl-containing tripeptide hcv serine protease inhibitors |
| 07/30/2009 | WO2009094427A1 4-pyridinone compounds and their use for cancer |
| 07/30/2009 | WO2009094426A1 13,13-dimethyl-des-c,d analogs of 1alpha, 25-dihydroxy-19-nor-vitamin d3 compounds and topical composition dosage forms and methods of treating skin conditions thereof |
| 07/30/2009 | WO2009094417A1 4-pyridinone compounds and their use for cancer |
| 07/30/2009 | WO2009094360A1 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib |
| 07/30/2009 | WO2009094287A1 Iap inhibitors |
| 07/30/2009 | WO2009094286A1 Hydrazines in glaucoma therapy |
| 07/30/2009 | WO2009094279A1 Quinolizidinone m1 receptor positive allosteric modulators |
| 07/30/2009 | WO2009094260A1 Kappa selective opioid receptor antagonist |
| 07/30/2009 | WO2009094242A1 Angiotensin ii receptor antagonists |
| 07/30/2009 | WO2009094224A1 Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| 07/30/2009 | WO2009094216A1 Derivatives of gefitinib |
| 07/30/2009 | WO2009094211A1 Quinazoline compounds and methods of treating cancer |
| 07/30/2009 | WO2009094210A1 Vandetanib derivatives |
| 07/30/2009 | WO2009094205A2 3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 07/30/2009 | WO2009094191A2 Methods of treating viral infections |
| 07/30/2009 | WO2009094190A2 Methods of treating viral infections |
| 07/30/2009 | WO2009094181A1 Ph-responsive nanostructures |
| 07/30/2009 | WO2009094177A1 Protopanaxadiol-type ginsenoside compositions and uses thereof |
| 07/30/2009 | WO2009094169A1 Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 07/30/2009 | WO2009094168A1 Cxcr3 antagonists |
| 07/30/2009 | WO2009094157A1 Dihydro- 1h- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists |
| 07/30/2009 | WO2009094155A1 In vivo studies of crystalline forms of meloxicam |
| 07/30/2009 | WO2009094123A1 Protein kinase inhibitors and use thereof |
| 07/30/2009 | WO2009094028A1 Aldh-2 inhibitors in the treatment of addiction |
| 07/30/2009 | WO2009093990A1 Benzimidazole derivatives and the use thereof |
| 07/30/2009 | WO2009093981A1 Triazine compounds as kinase inhibitors |
| 07/30/2009 | WO2009093972A1 Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising it - 026 |
| 07/30/2009 | WO2009093928A1 Agent for leg care against in case of chronic venous insufficiency of lower extremities |
| 07/30/2009 | WO2009093880A2 Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor |
| 07/30/2009 | WO2009093774A1 Method for treatment of anxiety disorder by regulating t-type calcium channel |
| 07/30/2009 | WO2009093761A1 Medicinal composition for inhibiting amyloid-β protein deposition |